New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Scientists learn what women know—and don't know—about breast density and cancer risk

Scientists learn what women know—and don't know—about breast density and cancer risk

byDartmouth-Hitchcock Medical CenterMammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public DomainBreast density is an important risk factor for breast cancer
Oncology December 22,2023
Scientists learn what women know—and don't know—about breast density and cancer risk

Scientists learn what women know—and don't know—about breast density and cancer risk

byDartmouth-Hitchcock Medical CenterMammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public DomainBreast density is an important risk factor for breast cancer
Oncology December 22,2023
A silent killer, liver cancer prompts race to improve organ replacements

A silent killer, liver cancer prompts race to improve organ replacements

by Anthony King,Horizon: The EU Research & Innovation MagazineBioprinter from Organtrans. Credit: © Gilles WederWith the only cure for liver cancer often being a transplantation, scientists
Oncology December 22,2023
A silent killer, liver cancer prompts race to improve organ replacements

A silent killer, liver cancer prompts race to improve organ replacements

by Anthony King,Horizon: The EU Research & Innovation MagazineBioprinter from Organtrans. Credit: © Gilles WederWith the only cure for liver cancer often being a transplantation, scientists
Oncology December 22,2023
Breast cancer patients with government insurance at higher risk of death

Breast cancer patients with government insurance at higher risk of death

by ECOG-ACRIN Cancer Research GroupSamilia Obeng-Gyasi, MD (The Ohio State University) is the lead author on an analysis of the insurance status of 9800 breast cancer patients and their clinical outco
Oncology December 22,2023
Breast cancer patients with government insurance at higher risk of death

Breast cancer patients with government insurance at higher risk of death

by ECOG-ACRIN Cancer Research GroupSamilia Obeng-Gyasi, MD (The Ohio State University) is the lead author on an analysis of the insurance status of 9800 breast cancer patients and their clinical outco
Oncology December 22,2023
Liver cancer: How liver cells go astray

Liver cancer: How liver cells go astray

byUniversity of BaselOne of the main causes of liver cancer is excessive alcohol consumption. Credit: Biozentrum, University of BaselThe causes of liver cancer are manifold. In addition to metab
Oncology December 22,2023
Liver cancer: How liver cells go astray

Liver cancer: How liver cells go astray

byUniversity of BaselOne of the main causes of liver cancer is excessive alcohol consumption. Credit: Biozentrum, University of BaselThe causes of liver cancer are manifold. In addition to metab
Oncology December 22,2023
Colorectal cancer initiation and progression: the role of low oxygen

Colorectal cancer initiation and progression: the role of low oxygen

byUniversity of LuxembourgScientists from the University of Luxembourg together with researchers from the Integrated Biobank of Luxembourg (IBBL) and the Luxembourg Institute of Health (LIH) hav
Oncology December 22,2023
Colorectal cancer initiation and progression: the role of low oxygen

Colorectal cancer initiation and progression: the role of low oxygen

byUniversity of LuxembourgScientists from the University of Luxembourg together with researchers from the Integrated Biobank of Luxembourg (IBBL) and the Luxembourg Institute of Health (LIH) hav
Oncology December 22,2023
Switch to plant-based diet could boost prostate cancer survival

Switch to plant-based diet could boost prostate cancer survival

by Steven ReinbergFollowing a healthy plant-based diet after a diagnosis of prostate cancer may help prevent the disease from progressing or recurring, a new study suggests.Men who ate adiet&nbs
Oncology December 22,2023
Switch to plant-based diet could boost prostate cancer survival

Switch to plant-based diet could boost prostate cancer survival

by Steven ReinbergFollowing a healthy plant-based diet after a diagnosis of prostate cancer may help prevent the disease from progressing or recurring, a new study suggests.Men who ate adiet&nbs
Oncology December 22,2023
Acute leukemia patients treated with common therapy have increased risk for heart failure

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh
Oncology December 22,2023
Acute leukemia patients treated with common therapy have increased risk for heart failure

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh
Oncology December 22,2023
Improving emotional well-being, quality of sleep, and decision making in patients at risk for breast cancer

Improving emotional well-being, quality of sleep, and decision making in patients at risk for breast cancer

byTel Aviv UniversityCredit: Pixabay/CC0 Public DomainA new study conducted at Tel Aviv University has determined that use of the Inquiry Based Stress Reduction (IBSR) technique among women with
Oncology December 22,2023
Improving emotional well-being, quality of sleep, and decision making in patients at risk for breast cancer

Improving emotional well-being, quality of sleep, and decision making in patients at risk for breast cancer

byTel Aviv UniversityCredit: Pixabay/CC0 Public DomainA new study conducted at Tel Aviv University has determined that use of the Inquiry Based Stress Reduction (IBSR) technique among women with
Oncology December 22,2023
Improving treatment for hairy cell leukemia

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon
Oncology December 22,2023
Improving treatment for hairy cell leukemia

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon
Oncology December 22,2023
Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m
Oncology December 22,2023
Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m
Oncology December 22,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com